Shots:

• Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer
• Accordingly- Novartis will acquire equity stake in Laenka adding upfront fees and milestones including royalties
• A second agreement b/w them in addition CFG920(CYP17 inhibitor) licensing- an oral androgen inhibitor- for prostate cancer

Ref: US FDA | Image: Crunchbase